000099228 001__ 99228
000099228 005__ 20210902121935.0
000099228 0247_ $$2doi$$a10.3390/jcm9124128
000099228 0248_ $$2sideral$$a122741
000099228 037__ $$aART-2020-122741
000099228 041__ $$aeng
000099228 100__ $$aEspiau-Romera, P.
000099228 245__ $$aMolecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
000099228 260__ $$c2020
000099228 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099228 5203_ $$aPancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is an extremely lethal disease due to late diagnosis, aggressiveness and lack of effective therapies. Considering its intrinsic heterogeneity, patient stratification models based on transcriptomic and genomic signatures, with partially overlapping subgroups, have been established. Besides molecular alterations, PDAC tumours show a strong desmoplastic response, resulting in profound metabolic reprogramming involving increased glucose and amino acid consumption, as well as lipid scavenging and biosynthesis. Interestingly, recent works have also revealed the existence of metabolic subtypes with differential prognosis within PDAC, which correlated to defined molecular subclasses in patients: lipogenic subtype correlated with a classical/progenitor signature, while glycolytic tumours associated with the highly aggressive basal/squamous profile. Bioinformatic analyses have demonstrated that the representative genes of each metabolic subtype are up-regulated in PDAC samples and predict patient survival. This suggests a relationship between the genetic signature, metabolic profile, and aggressiveness of the tumour. Considering all this, defining metabolic subtypes represents a clear opportunity for patient stratification considering tumour functional behaviour independently of their mutational background.
000099228 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/ES/ISCIII-FSE/El FSE invierte en tu futuro$$9info:eu-repo/grantAgreement/ES/MS-ISCIII-FSE/CP16-00121
000099228 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099228 590__ $$a4.241$$b2020
000099228 591__ $$aMEDICINE, GENERAL & INTERNAL$$b39 / 169 = 0.231$$c2020$$dQ1$$eT1
000099228 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000099228 700__ $$aCourtois, S.
000099228 700__ $$aParejo-Alonso, B.
000099228 700__ $$0(orcid)0000-0002-8624-8757$$aSancho, P.
000099228 773__ $$g9, 12 (2020), 4128 [21 pp]$$pJ. clin.med.$$tJOURNAL OF CLINICAL MEDICINE$$x2077-0383
000099228 8564_ $$s479344$$uhttps://zaguan.unizar.es/record/99228/files/texto_completo.pdf$$yVersión publicada
000099228 8564_ $$s2646408$$uhttps://zaguan.unizar.es/record/99228/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099228 909CO $$ooai:zaguan.unizar.es:99228$$particulos$$pdriver
000099228 951__ $$a2021-09-02-10:57:40
000099228 980__ $$aARTICLE